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General method: 
All reactions were performed under a nitrogen or argon atmosphere using standard inert 
gas techniques. Glassware for reactions were oven/flame dried in preparation for usage. 
All reagents and anhydrous solvents were purchased from commercial sources and used 
without further purification. Microwave catalyzed reactions were performed on a Biotage 
Initiator+ and sealed vials were purged with argon gas. The progresses of reactions were 
monitored using analytical thin-layer chromatography (TLC) on aluminum-backed pre-
coated silica plates (Silicycle, SiliaPlate 200 μM thickness, F254) and visualized by UV 
absorbance. Flash chromatography purifications were performed using a Biotage® 
Isolera Chromatography system with 10g and 25g Ultra-SNAP Cartridge columns (25 
μm spherical silica).  1H NMR spectra were obtained using a Bruker (300 or 400 MHz) or 
 2 
a Varian (400 or 500 MHz).  Chemicals shifts are reported in ppm and calibrated based 
on known solvent peaks (
1
H using CDCl3 = 7.26 ppm, MeOD = 3.31 ppm, DMSO, 2.50 
ppm; 
13
C using CDCl3 = 77.16 ppm, MeOD = 49.00 ppm, DMSO, 39.52 ppm).
[1]
 Spectral 
data was reported using the following abbreviations: (s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet, dd = doublet of doublets), coupling constants are reported in Hz, 
followed by integration. 
13
C NMR spectra were obtained at 126 MHz on a Varian 500 
MHz instrument with a proton decoupled probe. 
13
C spectra are reported with observed 
carbon-fluorine splitting and couplings constants are reported with relation to CF bond 
(JCF1 = CF bond, JCF2 = ortho to CF bond, JCF3 = meta to CF bond).  Data from MS 
spectrometry and HPLC traces were obtained using a Shimadzu LCMS 20-20 system, 
which was equipped with photo diode UV detector and a Kinetex® 2.6 μm, XB-C18 100 
Å, 75 x 4.6 mm column. HPLC traces were obtained at room temperature using a 
gradient method from 1% to 90% MeCN in H2O with 0.01% formic acid over 20 
minutes. The flow rate was 0.50 mL/min. Semi-preparative purifications were performed 
at room temperature on a Shimadzu LC-20 modular HPLC system, which was equipped 
with a photo diode UV detector and a Kinetex® 5 μm XB-C18 100 Å, 150 x 21.2 mm 
column. Semi-preparative purification was performed using a gradient method from 10% 
to 90% MeCN in H2O with 0.01% trifluoroacetic acid over 30 minutes.  
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Supplemental scheme 1: Synthesis of intermediate 5 
 
2-(4-Bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid (2): 5-
Fluoroindoline-2,3-dione (1.90 g, 11.5 mmol) and KOH (3.89 g, 69.6 mmol) were 
dissolved in 19 mL EtOH and the solution was stirred at room temperature. After 15 min, 
1-(4-bromophenyl)propan-1-one (2.45 g, 11.5 mmol) was added and the mixture was 
heated at reflux for 18 h. Upon completion, the mixture was cooled to room temperature 
and EtOH was removed in vacuo. The solution was washed with ethyl acetate (3x) and 
then acidified with aqueous HCl until pH 2-3 was reached. Product precipitation was 
observed and the solid was collected over a frit. 2-(4-Bromophenyl)-6-fluoro-3-
methylquinoline-4-carboxylic acid was isolated as a tan solid and used without further 
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purification (3.70 g, 10.3 mmol, 89%). 
1
H NMR (500 MHz, DMSO-d6) δ = 8.14 – 8.10 
(m, 1H), 7.73 – 7.67 (m, 3H), 7.57 (d, J = 8.1 Hz, 2H), 7.51 – 7.47 (m, 1H), 2.39 (s, 3H). 
13
C NMR (126 MHz, DMSO-d6) δ = 168.70, 160.82 (d, J CF1= 247.0 Hz)., 159.03, 
143.31, 140.91, 139.38, 132.75 (d, JCF3= 9.6 Hz), 131.67 (2C), 131.57 (2C), 125.76, 
123.70 (d, JCF3 = 10.2 Hz), 122.53, 120.15 (d, JCF2 = 25.7 Hz), 108.15 (d, JCF2 = 23.1 Hz), 
18.11. MS (ESI+) 360.00, 361.95 [M+H] 358.10, 360.15 [M-H].  
 
Methyl 2-(4-bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylate (3): 2-(4-
Bromophenyl)-6-fluoro-3-methylquinoline-4-carboxylic acid (6.50 g, 18.1 mmol) and 
Cs2CO3 (7.06 g, 21.7 mmol) were dissolved in 90 mL anhydrous DMF and the solution 
was stirred for 15 min at room temperature under an argon atmosphere. Methyl iodide 
(2.27 mL, 36.5 mmol) was added drop-wise to the solution and the reaction was stirred at 
room temperature for an additional 12 hours. The mixture was diluted with brine and 
product was extracted with EtOAc (3x). The combined EtOAc was washed with brine 
(6x), dried with magnesium sulfate, and concentrated in vacuo. Purification via flash 
chromatography (2:1 hexane/EtOAc) yielded methyl 2-(4-bromophenyl)-6-fluoro-3-
methylquinoline-4-carboxylate as white powder (6.02 g, 16.1 mmol, 89%). 
1
H NMR 
(500 MHz, Chloroform-d) δ = 8.11 (dd, J = 9.2, 5.4 Hz, 1H), 7.64 (d, J = 8.3 Hz, 2H), 
7.50 – 7.41 (m, 3H), 7.37 (d, J = 9.5, 2.7 Hz, 1H), 4.09 (s, 3H), 2.40 (s, 3H). 13C NMR 
(126 MHz, Chloroform-d) δ 168.01, 161.27 (d, JCF1= 249.5 Hz), 158.94, 143.53, 139.07, 
139.04, 132.44 (d, JCF3= 9.4 Hz), 131.76 (2C), 130.73 (2C), 126.64, 124.31 (d, JCF3= 10.3 
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Hz), 123.13, 119.91 (d, JCF2= 25.8 Hz), 108.00 (d, JCF2= 23.4 Hz), 52.95, 18.18. MS 
(ESI+) 373.95, 375.95 [M+H] 
 
Methyl 2-(4'-((tert-butyldimethylsilyl)oxy)-[1,1'-biphenyl]-4-yl)-6-fluoro-3-
methylquinoline-4-carboxylate (4): Methyl 2-(4-bromophenyl)-6-fluoro-3-
methylquinoline-4-carboxylate (652 mg, 1.75 mmol) and (4-((tert-
butyldimethylsilyl)oxy)phenyl)boronic acid (661 mg, 2.62 mmol) were dissolved in a 
degassed mixture of 10 mL toluene/5 mL H2O in a microwave vial. Pd(PPh3)4 (202 mg, 
0.17 mmol) and Na2CO3 (1.06 g, 10.0 mmol) were added to the mixture, the vial was 
sealed, and then heated at 130 °C for 2 h. Toluene was removed under reduced pressure 
and the mixture was extracted with EtOAc (3x), dried with magnesium sulfate, filtered, 
and concentrated. The residue was loaded onto a silica column and eluted in a gradient of 
9:1 hexane/EtOAc to yield methyl 2-(4'-((tert-butyldimethylsilyl)oxy)-[1,1'-biphenyl]-4-
yl)-6-fluoro-3-methylquinoline-4-carboxylate as a yellow oil (627 mg, 1.25 mmol, 72%). 
1
H NMR (500 MHz, Chloroform-d) δ 8.16 (dd, J = 3.8, 1.1 Hz, 1H), 7.72 – 7.67 (m, 2H), 
7.64 – 7.60 (m, 2H), 7.57 – 7.52 (m, 2H), 7.50 – 7.45 (m, 1H), 7.42 – 7.37 (m, 1H), 6.95 
(d, J = 7.4 Hz, 2H), 4.11 (s, 3H), 2.48 (s, 3H), 1.03 (s, 9H), 0.26 (s, 6H). 
13
C NMR (126 
MHz, Chloroform-d) δ 168.20, 161.15 (d, J CF1= 248.9 Hz)., 159.94, 155.70, 143.59, 
141.26, 138.87, 138.82, 138.44, 133.76, 132.46 (d, JCF3 = 9.2 Hz), 129.44 (2C), 128.25 
(2C), 126.95, 126.85 (2C), 124.18 (d, JCF3 = 10.2 Hz), 120.55 (2C), 119.65 (d, JCF2 = 25.7 
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Hz), 107.93 (d, JCF2 = 23.4 Hz), 52.87, 25.82 (3C), 18.36, -4.24 (2C). MS (ESI) 502.25 
[M+H]  
 
Methyl 6-fluoro-2-(4'-hydroxy-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-
carboxylate (5): Methyl 2-(4'-((tert-butyldimethylsilyl)oxy)-[1,1'-biphenyl]-4-yl)-6-
fluoro-3-methylquinoline-4-carboxylate (627 mg, 1.25 mmol) was dissolved in 12 mL 
THF. TBAF (392 mg, 1.50 mmol) was slowly added to the solution and the mixture was 
stirred at room temperature for 2 hour. Upon completion, the reaction mixture was 
concentrated, the residue was washed with a saturated solution of aqueous NH4Cl, and 
the product was extracted with EtOAc. The organic layer was dried with sodium sulfate, 
filtered, concentrated, and purified via flash chromatography using 1:1 EtOAc/Hexane to 
yield methyl 6-fluoro-2-(4'-hydroxy-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-
carboxylate (209 mg, 0.54 mmol, 43%). 
1
H NMR (500 MHz, DMSO-d6) δ 9.63 (s, 1H), 
8.16 – 8.12 (m, 1H), 7.75 – 7.68 (m, 2H), 7.68 – 7.64 (m, 2H), 7.61 – 7.53 (m, 3H), 6.89 
(d, J = 8.5, 1.5 Hz, 2H), 4.07 (s, 3H), 2.41 (s, 3H). 
13
C NMR (126 MHz, DMSO-d6) δ 
167.25, 160.44 (d, JCF1 = 246.5 Hz), 159.39, 157.43, 142.92, 140.30, 138.64, 138.60, 
137.52, 132.27 (d, JCF3 = 9.5 Hz), 129.64 (2C), 127.85 (2C), 126.45, 125.58 (2C), 123.27 
(d, JCF3 = 11.0 Hz), 119.77 (d, JCF2 = 25.9 Hz), 115.82 (2C), 107.82 (d, JCF2 = 23.2 Hz), 
53.14, 17.84. MS (ESI) 388.10 [M+H]  
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Supplemental scheme 2: Synthesis of intermediate 6.  
 
2-(2-(2-(Benzyloxy)ethoxy)ethoxy)ethan-1-ol (18): Compound 18 was prepared 
following a modified protocol described by Jiang & Yu.
[2]
 Triethylene glycol (17) (3.97 
mL, 29.8 mmol) was dissolved in THF (46 mL) and the solution was chilled to 0 °C. 
After 15 min, NaH (1.20 g, 30.1 mmol) was added and the mixture was stirred for an 
additional 15 min before adding benzyl bromide (2.10 mL, 17.5 mmol). The reaction 
mixture was warmed to room temperature overnight. Upon quenching with water, the 
mixture was concentrated and then extracted with EtOAc. The dried extracts were 
concentrated to a residue that was purified via flash chromatography eluting with 1:1 
hexane/EtOAc to yield 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethan-1-ol as a clear oil (2.09 
g, 8.74 mmol, 50%). 
1
H NMR (500 MHz, Chloroform-d) δ 7.37 – 7.31 (m, 4H), 7.28 – 
7.20 (m, 1H), 4.54 (s, 2H), 3.76 – 3.51 (m, 12H). 13C NMR (126 MHz, Chloroform-d) δ 
138.06, 128.41 (2C), 127.83 (2C), 127.70, 73.28, 72.60, 70.63, 70.57, 70.32, 69.36, 
61.67. MS (ESI) 241.70 [M+H]  
 
 
2-(2-(2-(Benzyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (6): 2-(2-(2-
(Benzyloxy)ethoxy)ethoxy)ethan-1-ol (18) (2.09 g, 8.74 mmol)) was dissolved in 60 mL 
of THF and 20 mL of H2O. KOH (1.71 g, 30.5 mmol) was added to the mixture, which 
was stirred at room temperature for 15 min before TsCl (2.00 g, 10.5 mmol) was added 
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and the mixture for stirred overnight. Upon completion, the mixture was poured into a 
saturated solution of ammonium hydroxide and extracted with dichloromethane (3x). The 
extract was pooled, dried with magnesium sulfate, filtered, and concentrated to yield 2-
(2-(2-(benzyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate as a orange oil (2.50 g, 
6.33 mmol, 72%), which was used without further purification. 
1
H NMR (500 MHz, 
Chloroform-d) δ 7.79 (d, J = 8.3 Hz, 2H), 7.38 – 7.21 (m, 7H), 4.55 (s, 2H), 3.71 – 3.57 
(m, 12H), 2.43 (s, 3H). 
13
C NMR (126 MHz, Chloroform-d)) δ 144.91, 138.36, 129.94 
(2C), 128.51 (2C), 128.13 (2C), 127.89 (2C), 127.76 (2C), 73.39, 70.93, 70.83, 70.73, 
69.55, 69.38, 68.85, 21.78. MS (ESI) 395.15 [M+H].  
Supplemental scheme 3: Synthesis of intermediate 9.  
 
4-(4-Methylthiazol-5-yl)benzonitrile (20): Compound 20 was prepared following a 
protocol that was reported by Buckley
[3]
 and Galdeno
[4]
. A mixture containing 4-
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bromobenzonitrile (5.00 g, 27.5 mmol), 4-methylthiazole (4.98 mL, 54.7 mmol), KOAc 
(5.40 g, 55.0 mmol), and palladium acetate (62.0 mg, 0.27 mmol) were dissolved in 16 
mL DMAc. The mixture was heated to 140 °C overnight, cooled, and then poured into 
EtOAc. The solution was washed with H2O (6x), dried with magnesium sulfate, filtered, 
and concentrated. The resulting oil was crystallized by the addition of hexanes and used 
without further purification. 4-(4-Methylthiazol-5-yl)benzonitrile was isolated as a 
yellow solid (5.15 g,  25.8 mmol, 94%) and matched the reported spectral data.
[4]
 
1
H 
NMR (400 MHz, Chloroform-d) δ 8.76 (s, 1H), 7.75 – 7.71 (m, 2H), 7.60 – 7.55 (m, 2H), 
2.59 – 2.56 (m, 3H). MS (ESI) 200.90 [M+H].  
 
(4-(4-Methylthiazol-5-yl)phenyl)methanamine (21): Compound 21 was prepared 
following a protocol reported by Buckley
[3]
 and Galdeno.
[4]
 Compound 20 (5.15 g, 25.8 
mmol) was dissolved in 280 mL anhydrous MeOH. Cobalt chloride hexahydrate (9.90 g, 
41.7 mmol) was added and the solution was placed on an ice bath for 30 min. NaBH4 
(5.22 g, 138 mmol) was slowly added over 20 min, bubbling was observed, and the 
solution turned black. The mixture was stirred for 90 min and quenched with cold H2O. 
The quenched solution was poured over a frit to remove insoluble by-products and the 
filtrate was washed with H2O then extracted with EtOAc.  The organic layer was dried 
with sodium sulfate, filtered, concentrated, and purified via flash chromatography using a 
gradient of 1-10% 0.5 M methanolic ammonia in DCM. Compound 21 was isolated (1.12 
g, 5.49 mmol, 21%) and matched the reported spectral data.
[3]
 
1
H NMR (400 MHz, 
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Chloroform-d) δ 8.65 (s, 1H), 7.41 – 7.35 (m, 4H), 3.90 (s, 2H), 2.50 (s, 3H). MS (ESI) 
204.90, 187.80 (fragmentation product reported by Galdeno also observed)
[3-4]
 [M+H].  
 
 (4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (22): 
Compound 22 was prepared following a protocol reported by Galdeno
[4]
. Anhydrous 
DMF (55 ml) was added to a round-bottom flask containing compound 21 (1.12 g, 5.49 
mmol), Boc-Hyp-OH (1.27 g, 5.49 mmol), DIPEA (3.85 mL, 22.0 mmol), and HATU 
(2.30 g, 6.05 mmol).  The mixture was stirred at room temperature overnight. The 
solution was diluted with H2O and extracted with EtOAc. The EtOAc layer was washed 
with brine (6x), dried with magnesium sulfate, and concentrated. The residue was 
purified via flash chromatography using a gradient from 1-10% 0.5 M methanolic 
ammonia in DCM. (MS (ESI) 418.15 [M+H]). The isolated oil was re-dissolved in 10 mL 
of 4.0 N HCl in dioxane and stirred at room temperature for 1 h. The solvent was 
concentrated and used without further purification. Compound 22 was isolated as an oil 
(1.16 g, 3.66 mmol, 66% two steps) and matched the reported spectral data.
[3]
 
1
H NMR 
(300 MHz, Chloroform-d) δ 8.69 (s, 1H), 8.28 – 8.04 (m, 1H), 7.45 – 7.32 (m, 4H), 4.52 
– 4.44 (m, 3H), 4.10 (t, J = 8.4 Hz, 1H), 3.10 – 3.00 (m, 1H), 2.88 – 2.77 (m, 1H), 2.54 
(s, 3H), 2.41 – 2.32 (m, 1H), 2.07 – 1.93 (m, 1H). MS (ESI) 317.90 [M+H]  
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 (4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (9): A mixture containing compound 22 (1.16 g, 
3.29 mmol), Boc-L-tert-leucine (847 mg, 3.67 mmol), HATU (1.67 g, 4.40 mmol), and 
DIPEA (2.56 mL, 14.7 mmol) was dissolved in 55 mL DMF. The mixture was stirred at 
room temperature overnight, diluted with H2O, and extracted with EtOAc.. The EtOAc 
layer was washed with a saturated NaHCO3 solution (2x), brine (6x), dried with 
magnesium sulfate, filtered, and concentrated. (MS (ESI) 531.10 [M+H]) Residue 
containing the intermediate was dissolved in 10 mL of 4.0 N HCl in dioxane, stirred at 
room temperature for 1 hour, and followed the workup described by Buckner.
[3]
 The 
solution was concentrated to an orange oil and matched the reported spectra of  (4R)-1-
((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (970 mg, 2.25 mmol, 68% yield two steps) and 
used without further purification. 
1
H NMR (300 MHz, Methanol-d4) δ 8.90 (s, 1H), 7.50 
– 7.41 (m, 4H), 4.66 – 4.34 (m, 4H), 3.82 – 3.65 (m, 1H), 3.49 (s, 1H), 2.50 (s, 3H), 2.30 
– 2.17 (m, 1H), 2.16 – 2.07 (m, 1H), 1.04 (s, 9H). MS (ESI) 431.15 [M+H].  
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Supplemental scheme 4: Synthesis of probe 10. 
 
Methyl 2-(4'-(2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethoxy)-[1,1'-biphenyl]-4-yl)-6-
fluoro-3-methylquinoline-4-carboxylate (7): Compound 5 (209 mg, 0.54 mmol) was 
dissolved in 11 mL DMF. Cs2CO3 (790 mg, 2.42 mmol) was added to the solution and the 
mixture was stirred at room temperature for 5 min. 2-(2-(2-
(Benzyloxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (6) (255 mg, 0.65 mmol), 
was slowly added and the mixture was heated at 75 °C for 2 h. The solution was 
concentrated to an oil, re-dissolved in DCM, washed with brine (6x), dried with 
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magnesium sulfate, and re-concentrated to an oil. The crude was purified by silica 
chromatography eluting with a gradient from 10% to 40% EtOAc in hexane. Methyl 2-
(4'-(2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethoxy)-[1,1'-biphenyl]-4-yl)-6-fluoro-3-
methylquinoline-4-carboxylate was isolated (173 mg, 0.28 mmol, 52%) and used without 
further purification. 
1
H NMR (500 MHz, Chloroform-d) δ 8.20 – 8.15 (m, 1H), 7.71 – 
7.66 (m, 2H), 7.61 (d, J = 8.3 Hz, 2H), 7.60 – 7.56 (m, 2H), 7.51 – 7.46 (m, 1H), 7.41 – 
7.25 (m, 6H), 7.04 – 7.00 (m, 2H), 4.58 (s, 2H), 4.22 – 4.17 (m, 2H), 4.11 (s, 3H), 3.93 – 
3.88 (m, 2H), 3.80 – 3.63 (m, 8H), 2.48 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 
168.23, 162.20, 161.21 (d, JCF1 = 249.1 Hz). 159.93, 158.79, 143.53, 141.23, 138.42, 
133.39, 132.43 (d, JCF3 = 9.7 Hz), 129.49 (2C), 128.50 (2C), 128.30 (2C), 127.87 (2C), 
127.72, 127.00, 126.88 (2C), 124.23 (d, JCF3 = 10.1 Hz), 119.76 (d, JCF2 = 25.7 Hz), 
115.17 (2C), 110.14, 107.97 (d, JCF2 = 23.4 Hz)., 73.39, 71.04, 70.87 (2C), 69.91, 69.60, 
67.70, 52.94, 18.34. MS (ESI) 610.45 [M+H].  
 
Methyl 6-fluoro-2-(4'-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-[1,1'-biphenyl]-4-yl)-3-
methylquinoline-4-carboxylate (8): Compound 7 (173 mg, 0.28 mmol) was dissolved in 
30 mL anhydrous EtOH and the solution was purged with argon for 30 min. Activated Pd 
on charcoal (10%) (60 mg) was added to the solution, (excess EtOH was used to 
submerge all Pd/C) and the mixture was stirred under an H2 environment overnight. The 
mixture was filtered over EtOAc washed celite and eluted with EtOAc. Filtrate was 
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concentrated and loaded onto silica column eluting with a gradient of 20 – 66% EtOAc in 
hexane. Compound 8 was isolated (79 mg, 0.15 mmol, 54%).  
1
H NMR (500 MHz, 
Chloroform-d) δ 8.21 (s, 1H), 7.69 (d, J = 8.3 Hz, 2H), 7.64 – 7.56 (m, 4H), 7.52 – 7.45 
(m, 1H), 7.38 (dd, J = 9.5, 2.7 Hz, 1H), 7.07 – 6.99 (m, 2H), 4.24 – 4.18 (m, 2H), 4.11 (s, 
3H), 3.94 – 3.88 (m, 2H), 3.79 – 3.69 (m, 6H), 3.69 – 3.61 (m, 2H), 2.48 (s, 3H). 13C 
NMR (126 MHz, Chloroform-d) δ 168.16, 161.25 (d, JCF1 = 249.2 Hz), 159.85, 158.71, 
143.29, 141.31, 138.16, 133.47 (2C, overlap), 132.26 (d, J CF3 = 10.1 Hz), 129.54 (2C), 
128.35 (2C), 127.08, 126.90 (2C), 124.28 (d, JCF3 = 9.9 Hz), 119.90 (d, JCF2 = 25.5 Hz), 
115.17 (2C), 108.00 (d, JCF2 = 23.7 Hz), 72.64, 71.02, 70.55, 69.91, 67.64, 61.94, 52.98, 
18.33. MS (ESI) 520.30 [M+H].   
 
 Methyl 6-fluoro-2-(4'-(((12S)-12-((4R)-4-hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-13,13-dimethyl-10-oxo-3,6,9-trioxa-11-
azatetradecyl)oxy)-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylate (10): 
Compound 8 (40 mg, 0.08 mmol) was dissolved in 3 mL anhydrous MeCN. DIPEA (0.07 
mL, 0.39 mmol) was added and the mixture was stirred at room temperature for 15 min. 
N,N’-disuccinimidyl carbonate (102 mg, 0.40 mmol) was added and the mixture was 
stirred at room temperature for 12 hours before being concentrated. The residue was 
dissolved in DCM and washed with H2O (3x). The organic layer was dried with 
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magnesium sulfate, filtered, concentrated, and used without further purification. In a 
separate round-bottom flask, compound 9 (34 mg, 0.08 mmol) was dissolved in DMF 
(2.0 mL) and DIPEA (0.07 mL, 0.39 mmol). The organic residue containing the 
succimidyl intermediate was dissolved in 1.5 mL DMF and the mixture was slowly added 
to the basic solution containing 9. The combined solution was stirred at room temperature 
for 12 hours. Upon completion, the mixture was concentrated to an oil, re-dissolved in 
EtOAc, and washed with brine (6x). The organic layer was dried with magnesium sulfate, 
filtered, concentrated, and loaded onto silica column, eluting in a slow gradient towards 
90/10 DCM/MeOH with 0.5 M NH4. Compound 10 was isolated as a clear oil (16 mg, 
0.02 mmol, 25% yield, two-steps). 
1
H NMR (500 MHz, Methanol-d4) δ 8.83 (s, 1H), 
8.10 (dd, J = 9.3, 5.4 Hz, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.64 – 7.57 (m, 5H), 7.47 – 7.36 
(m, 5H), 7.04 (d, J = 8.7 Hz, 2H), 4.58 (t, J = 8.3 Hz, 1H), 4.54 – 4.47 (m, 2H), 4.36 – 
4.31 (m, 2H), 4.23 – 4.13 (m, 4H), 4.10 (s, 3H), 3.91 – 3.83 (m, 3H), 3.78 (dd, J = 10.9, 
3.9 Hz, 1H), 3.74 – 3.65 (m, 6H), 2.44 (s, 3H), 2.41 (s, 3H), 2.25  – 2.17 (m, 1H), 2.13 – 
2.04 (m, 1H), 1.01 (s, 9H). 
13
C NMR (126 MHz, Methanol-d4) δ 174.40, 172.65, 169.00, 
162.55 (d JCF1 = 244.4 Hz), 161.55, 160.25, 158.57, 152.77, 149.00, 144.32, 142.56, 
140.91, 140.21, 139.20, 134.16, 133.38, 132.58 (d, J CF3 = 9.6 Hz), 131.48, 130.61 (2C), 
130.35 (2C), 129.15 (2C), 128.93, 128.46 (2C), 127.47 (2C), 125.51 (d, J CF3 = 10.1 Hz), 
120.94 (d, J CF2 = 26.2 Hz), 116.16 (2C), 108.98 (d, J CF2 = 23.9 Hz), 71.78, 71.59, 71.09, 
70.90, 70.51, 68.72, 65.44, 60.95, 60.81, 57.99, 53.43, 43.70, 38.90, 36.68, 26.95 (3C), 
18.32, 15.83. LCMS (ESI) 976.45 [M+H], 95% purity based on HPLC chromatograph at 
254 nm.  
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Supplemental scheme 5: Synthesis of probe 11. 
 
6-Fluoro-2-(4'-(((12S)-12-((4R)-4-hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-13,13-dimethyl-10-oxo-3,6,9-trioxa-11-
azatetradecyl)oxy)-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid (11): 
Compound 10 (10 mg, 0.01 mmol) was dissolved in a 1 mL solution of 1:1 THF/H2O. 
LiOH (5 mg, 0.21 mmol) was added to the solution and the mixture was stirred at room 
temperature overnight. LCMS indicated pre-dominantly starting material remained. 
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Additional LiOH (20 mg, 0.83 mmol) was added and the solution was heated to 40 °C for 
three additional days (reaction progress monitored by LCMS). The mixture was 
concentrated and purified via reverse phase chromatography eluting with a gradient from 
0 to 100 MeCN in H2O. Compound 11 was isolated as a clear oil (5 mg, 0.01 mmol, 
50%). 
1
H NMR (300 MHz, Methanol-d4) δ 8.87 (s, 1H), 8.08 – 8.00 (m, 1H), 7.76 (d, J = 
7.9 Hz, 2H), 7.70 – 7.56 (m, 5H), 7.57 – 7.39 (m, 5H), 7.09 (d, J = 8.3 Hz, 2H), 4.65 – 
4.49 (m, 3H), 4.41 – 4.33 (m, 2H), 4.26 – 4.13 (m, 4H), 3.96 – 3.84 (m, 3H), 3.84 – 3.62 
(m, 7H), 2.52 – 2.38 (m, 6H), 2.30 – 2.06 (m, 1H), 2.06 – 2.02 (m, 1H), 1.04 (s, 9H). 13C 
NMR (126 MHz, Methanol-d4) δ 174.43, 172.66, 161.92 (d, JCF1 = 247.0 Hz), 161.76, 
160.94, 160.16, 158.58, 152.82, 149.02, 144.26, 142.25, 140.23, 140.05, 135.47 (d, JCF2 = 
12.6 Hz), 134.39, 133.41, 131.57, 131.49, 130.50 (2C), 130.37 (2C), 129.15 (2C), 128.94 
(2C), 127.39 (2C), 125.78 (d,  JCF3 = 10.0 Hz), 124.87, 120.16 (d, JCF2 = 26.2 Hz), 116.13 
(2C), 110.22 (d, JCF2 = 22.8 Hz)., 71.78, 71.59, 71.10, 70.91, 70.53, 68.71, 65.44, 60.97, 
60.82, 57.98, 43.70, 38.92, 36.68, 26.94 (3C), 18.14, 15.81. LCMS (ESI) 962.45. [M+H], 
960.35 [M-H], 96% purity based on HPLC chromatograph at 254 nm. 
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Supplemental scheme 6: Synthesis of intermediate 15 and probe 16.  
 
1-(2'-Fluoro-[1,1'-biphenyl]-4-yl)propan-1-one: (12) 1-(4-Bromophenyl)propan-1-one 
(2.00 g, 9.39 mmol), (2-fluorophenyl)boronic acid (1.95 g, 14.1 mmol), K2HPO4 (3.89 g, 
28.2 mmol), and Pd(PPh3)4 (0.54 g, 0.47 mmol) were added to a microwave vial. 12 mL 
of dioxane and 2 mL of H2O were added and the vial was sealed. The reaction was stirred 
at 130 °C for 1.5 hour and the mixture was concentrated upon completion. The product 
was purified from the residue via flash chromatography with a gradient of 1% to 60% 
EtOAc in hexane to yield compound 12 (679 mg, 2.98 mmol, 32% yield). 
1
H NMR (500 
MHz, Chloroform-d) δ 8.02 (d, J = 8.4 Hz, 2H), 7.62 (dd, J = 8.4, 1.7 Hz, 2H), 7.43 (td, J 
= 7.8, 1.8 Hz, 1H), 7.36 – 7.30 (m, 1H), 7.21 (td, J = 7.6, 1.2 Hz, 1H), 7.18 – 7.12 (m, 
1H), 3.00 (q, J = 7.2 Hz, 2H), 1.24 (t, J = 7.2 Hz, 3H). MS (ESI) 229.05 [M+H].  
 19 
 
6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid 
(Brequinar) (13): 5-fluoroisatin (2.17 g, 13.2 mmol) was dissolved in a 35 mL solution of 
EtOH/H2O (2:1 ratio). KOH (2.95 g, 52.6 mmol) were added and the solution was stirred 
at room temperature for 15 min (solution turns dark when KOH is added). Compound 12 
(2.0 g, 8.77 mmol) was added and the mixture was heated at reflux overnight. Upon 
completion, the mixture was cooled to room temperature, dioxane/EtOH were 
concentrated in vacuo, and the solution was diluted with 1 M KOH. The basic solution 
was washed with EtOAc (3x) and then acidified to pH 2-3 with HCl (precipitant 
formation observed). Precipitant was poured over a fritted funnel then triturated with 
EtOAc and Et2O, before collection. Compound 13 isolated as a tan solid (1.81 g, 4.82 
mmol, 55%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.15 (dd, J = 9.2, 5.6 Hz, 1H), 7.79 – 
7.69 (m, 5H), 7.65 (t, J = 7.8, 1.7 Hz, 1H), 7.54 – 7.45 (m, 2H), 7.41 – 7.32 (m, 2H), 2.47 
(s, 3H).  
13
C NMR (126 MHz, DMSO-d6) δ 168.38, 160.34 (d, JCF1 = 245.7 Hz), 160.16, 
159.35, 159.28, 158.20, 142.94, 139.26, 135.17, 132.32 (d, JCF3 = 10.0 Hz), 130.82 (d, 
JCF4 = 3.3 Hz), 129.87 (d, JCF3 = 10.1 Hz), 129.38 (2C), 128.59 (d, JCF4 = 2.9 Hz), 127.73 
(d, JCF3 = 13.9 Hz), 125.34, 125.07 (d, JCF4 = 3.6 Hz), 119.67 (d, JCF2 = 25.7 Hz), 116.21 
(d, JCF2 = 22.5 Hz), 107.72 (d, JCF2 = 23.4 Hz), 17.77. MS (ESI) 375.70 [M+H], 373.65 
[M-H].  
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(3-Aminopropyl)triphenylphosphonium (15);  Compound 15 was prepared following a 
modified protocol from Zeng et al.
[5]
 3-bromopropan-1-amine (14) (1.0 g 4.56 mmol) was 
dissolved in 20 mL of n-BuOH. Triphenylphosphine (1.19 g, 4.56 mmol) was added and 
the mixture was heated at reflux overnight.  The reaction mixture was cooled to RT for 
15 min before the addition of 12 mL of hexanes. The mixture was then stirred for 30 min 
and filtered over a frit. The white solid was washed with another 12 mL hexane (2x) 
before triturating with a 50/50 solution of t-butyl methyl ether and hexane (3x). (3-
Aminopropyl)triphenylphosphonium was isolated (1.69 g, 4.24 mmol, 93%) and used 
without further purification. 
1
H NMR (500 MHz, DMSO-d6) δ 7.94 – 7.73 (m, 15H), 
3.98 – 3.86 (m, 2H), 3.10 – 3.02 (m, 2H), 1.97 – 1.82 (m, 2H). 13C NMR (126 MHz, 
DMSO-d6) δ 135.56 (d, JCP4 = 3.1 Hz) (3C), 134.06 (d, JCP3 = 10.2 Hz) (6C), 130.83 (d, 
JCP2 = 12.5 Hz) (6C), 118.47 (d, JCP1 = 86.0 Hz) (3C), 39.24, 20.53, 18.88 (d, JCP1 = 52.8 
Hz). MS (ESI) 320.15 [M+H].   
 
(3-(6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-
carboxamido)propyl)triphenylphosphonium (16): Compound 13 (102 mg, 0.27 mmol) 
was dissolved in 3 mL of anhydrous 1,2 DCE. SOCl2 (0.11 mL, 1.51 mmol) and 1 drop of 
DMF were added slowly then the mixture was heated at 60 °C for 2 h.  (Acid chloride 
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formation was monitored via TLC; 1 drop of reaction mixture was added to a vial 
containing TEA and MeOH, then the mixture was checked for the presence of methyl 
ester). The reaction mixture was cooled to room temperature, concentrated, re-dissolved 
in 1,2 DCE, and re-concentrated. The acid chloride was re-dissolved in 3 mL 1,2 DCE 
and slowly added to a separate round bottom flask, which contained a stirring solution of 
compound 15 (130 mg, 0.33 mmol), DIPEA (0.30 mL, 1.72 mmol), and 2.00 mL of 
anhydrous 1,2 DCE chilled over an ice bath. (Gas release was observed when the acid 
chloride was added to the solution). The mixture was stirred overnight. Upon completion, 
the mixture was concentrated, loaded onto silica column and eluted in a 1-30 % MeOH 
gradient in DCM with 0.5 M NH3. Fractions containing desired compound was 
concentrated, re-dissolved in MeCN and crystallized by the addition of Et2O/Hexane. The 
precipitant was poured over a frit and triturated with cold EtOAc, Et2O, t-Butyl methyl 
ether, and hexane. Compound 16 was isolated as a tan solid with a red tint (89 mg, 0.13 
mmol, 48%). 
1
H NMR (500 MHz, DMSO-d6) δ 8.88 (t, J = 5.6 Hz, 1H), 8.12 (dd, J = 
9.2, 5.5 Hz, 1H), 7.95 – 7.74 (m, 15H), 7.74 – 7.66 (m, 4H), 7.63 (t, J = 8.0 Hz, 1H), 7.50 
– 7.42 (m, 1H), 7.40 – 7.33 (m, 3H), 3.72 – 3.54 (m, 4H), 2.32 (s, 3H), 1.94 – 1.81 (m, 
2H). 
13
C NMR (126 MHz, DMSO-d6) δ 166.72, 160.67 (d, JCF1 = 248.2 Hz), 159.62 (d, 
JCF1 = 247.0 Hz), 159.57, 143.45, 143.41, 139.79, 135.63, 135.51 (d, JCP4 = 3.1 Hz) (3C), 
134.03 (d, JCP3 = 10.3 Hz) (6C), 132.62 (d, JCF3 = 10.0 Hz), 131.25 (d, JCF4 = 3.3 Hz), 
130.81, 130.76 (d, JCP2 = 12.4 Hz) (6C), 130.35 (d, J = 8.1 Hz), 129.74, 129.09 (d, J = 
3.0 Hz), 128.14 (d, JCF3 = 13.0 Hz), 125.91, 125.54 (d, JCF4 = 3.4 Hz), 124.54 (d, JCF3 = 
10.1 Hz), 119.99 (d, JCF2 = 25.5 Hz), 118.70 (d, JCP1 = 86.0 Hz) (3C), 116.68 (d, JCF2 = 
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22.5 Hz), 108.43, 108.25, 25.94, 22.56, 19.00 (d, JCP1 = 51.6 Hz), 17.86. LCMS (ESI) 
678.15 [M+H], 98% purity based on HPLC chromatograph at 254 nm 
hDHODH expression and purification 
The hDHODH construct was provided by the De Brabander lab at UT Southwestern.
[6] 
hDHODH was expressed in E. coli Rosetta 2 (DE3) in LB medium with ampicillin (100 
µg/mL) and 0.1 mM FMN. Cells were grown at 37 °C to OD600 = 0.6, then induced with 
1 mM IPTG for 3 hours. Cells were harvested by centrifugation at 4,000 x g for 15 min at 
4 °C. The pellet was re-suspended in lysis buffer (50 mM Tris-HCl, pH 8.5, 300 mM 
NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 10 mM imidazole, 2% Triton X-100, 0.5 
mM FMN, 200 µM PMSF, 1 mg/mL lysozyme). The cell suspension was incubated on 
ice for 2 hours, followed by sonication. The lysate was clarified by centrifugation at 
35,000 x g for 20 min at 4 °C. After the supernatant was incubated with Ni-NTA resin for 
1 h at 4 °C, the resin was loaded onto a column. The column was washed with wash 
buffer (50 mM Tris-HCl, pH 8.5, 300 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 
25 mM imidazole, 0.1 mM FMN) and hDHODH was eluted with elution buffer (wash 
buffer containing 300 mM imidazole). Buffer exchange was carried out using an Amicon 
concentrator into storage buffer (100 mM HEPES, pH 8.0, 150 mM NaCl, 10% glycerol) 
and hDHODH was stored at -80 °C. 
DHODH activity assay 
DHODH activity was monitored as previously described with modifications.
[7]
 First, 1 µL 
of test compound (50x) or DMSO, 60 nM DHODH, 100 µM DCIP, and 20 µM CoQ10 
(final concentrations for 50 µL) in the assay buffer (100 mM HEPES pH 8.0, 150 mM 
NaCl, 10% glycerol, 0.1% Triton X-100) in a total of 40 µL were incubated together for 
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30 min. The assay began with the addition of 10 µL of dihydroorotate to a final 
concentration of 200 µM. The reduction of DCIP was measured by monitoring the 
absorbance at 600 nm over 1 hr at room temperature using a microplate reader (BMG 
Labtech). Data were exported to Microsoft Excel for analysis and IC50 values were 
determined using Prism 6 software.  
Supplemental Figure 1: Western blot analysis of HCT116 p53+/+ cells, untreated or 
treated with compounds.  
No change of DHODH protein expression was observed in HCT116 p53+/+ cells after 
treatment of PROTAC compounds, precursor compound 5, VHL, or brequinar for 12 h.  
  
Supplemental Figure 2: Clonogenic assay performed on HCT116 p53+/+ cells after 
continuous treatment with varying doses of 10, 11, 5, VHL, or brequinar for 7d. 
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Microsomal stability studies to determine t1/2 
Assays to determine microsomal stability and t1/2 were performed by the University of  
Michigan Pharmacokinetics Core. A microsome solution was created, which contained 
10 μL of mouse liver microsome (20 mg/mL) in 330 μL 0.1 M phosphate buffer (3.3 mM 
MgCl2). Aliquots (40 μL) from stock solutions of test compounds (10 μM) were added 
and the mixture was incubated at 37 ℃ for 3 min. The enzymatic reactions were initiated 
by addition of 20 μL NADPH solution (freshly prepared containing 4 mg NADPH in 240 
μL of 0.1M phosphate buffer (3.3 mM MgCl2)). Aliquots of 40 μL were removed from 
reaction solutions and stopped by the addition of chilled acetonitrile, which contained 50 
ng/mL of CE302, an internal standard, at the designated time points (0, 5, 10, 15, 30, 45, 
and 60 min). Verapamil was used as positive control with the same method. The 
incubated solution was centrifuged at 3500 g for 15 minutes and the supernatant was used 
for LC/MS/MS analysis. A ratio of the natural log peak area (compound peak area/ 
internal standard peak area) was plotted against time and used for data extrapolation.  
Chromatographic conditions utilized a 5 cm x 2.1 mm I.D. 3.5 µm XBridge column from 
Waters and utilized a gradient method of 5-95% MeCN in H2O containing 0.1% formic 
acid.  
Cell culture 
HCT116 P53 +/+ and MiaPaca-2 cells were maintained in RPMI-1640 (Gibco) 
supplemented with 10% heat-inactivated FBS (Gibco). Cells were grown at 37 °C in a 
humidified atmosphere of 5% CO2. For subculture and counting, cells were washed with 
DPBS (Gibco) without calcium or magnesium, incubated with 0.25% trypsin-EDTA 
solution (Gibco) for 5 min, neutralized with full medium, centrifuged, re-suspended with 
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culture medium and counted by Countess II FL. All experiments were performed using 
cells in exponential growth. Cells were routinely checked for Mycoplasma 
contamination. 
Western blot 
HCT116 p53+/+ cells were seeded into 6-well microtiter plates for 4 x 10
5
 cells per well, 
and allowed to attach overnight before the addition of the dilution of compound (10X). 
After 12h treatment, the cells are lysated with RIPA buffer with the presence of protease 
inhibitors and phosphatase inhibitors. The cells are collected and centrifuged. The pellet 
was discarded. Protein concentration of whole-cell lysate in the supernatant was 
determined by BCA protein assay kit (Thermo Scientific). Proteins were resolved in 10% 
SDS/PAGE and electrotransferred to transfer membrane (Immobilon®-FL). After 
blocking with TBS blocking buffer (Thermo Scientific), membranes were probed with 
DHODH primary antibody (Santa Cruz Biotechnology; rabbit; 1:1000) and GAPDH 
primary antibody (Signaling; rabbit; 1:4000 ) in 5% BSA (EMD Millipore corporation) in 
TBST (Tris-buffered saline, 0.1% Tween 20) and then washed and incubated with goat 
anti-rabit IgG (H&L) secondary antibody (Dylight 800 4x PEG conjugated; Thermo 
Scientific; 1:4000). The membrane was imaged by Odyssey® CLx Imaging System. 
Clonogenic assay  
HCT116 p53+/+ cells were seeded 500 cells per well into 24-well plates for or 200 cells 
per well into 96-well plates, and allowed to attach overnight before the addition of 
compounds. After 7-day contentious treatment, the medium was removed and crystal 
violet solution was added to fix and stain the colonies for 20 min. Crystal violet was 
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removed and the colonies were washed with ddH2O for three times. The colonies were 
imaged by Odyssey® CLx Imaging System. 
Growth inhibition assay 
HCT116 p53+/+ cells or MiaPaCa-2 cells were seeded 2500-3000 cells per well in 96-
well microtiter plates, and allowed to attach overnight before the addition of the serial 
dilution of compounds (10X). After 72h, cells were incubated with 0.3 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (VWR) for an additional 3h at 37 
°C. After removal of the supernatant, DMSO was added to the wells, and the absorbance 
was read at 570 nm. All assays were performed in triplicate. Percentage of cell growth 
inhibition was expressed as (1 − A/C) × 100% (A and C were the absorbance values from 
experimental and control cells, respectively). IC50 values were determined for each drug 
from nonlinear regression analysis of log (drug concentration) vs. percentage of cell 
growth inhibition using Prism 7.0. SD or SEM was calculated based on the IC50 values 
obtained from at least three independent experiment. 
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